Within the body's vast immune architecture, not all defenders serve the same purpose — some, it turns out, become the very source of harm they were meant to prevent. Researchers at India's Central Drug Research Institute have identified a rogue subpopulation of neutrophils that linger far longer than their counterparts, driving chronic inflammation in conditions ranging from rheumatoid arthritis to fatty liver disease. The discovery, published in Cell Reports, suggests that the line between protection and destruction is drawn not by the immune system as a whole, but by specific cells within it
Scientists identify aggressive neutrophil subtype driving chronic inflammation
Some neutrophils linger and inflict tissue damage
Mark
So the basic finding is that some neutrophils are worse than others?
Mimi
Exactly. Most neutrophils do their job and move on. But this subpopulation sticks around and causes damage. They're especially abundant in the liver.
Luke
How do we know they're actually causing the damage and not just present during it? Correlation versus causation.
Mimi
Fair point. The researchers blocked a specific protein on these cells and saw inflammation and tissue damage decrease. That suggests active causation, not just association.
Mark
What transforms a normal neutrophil into one of these rogue cells?
Mimi
Inflammatory signals and metabolic stress—particularly poor liver health. The cells also accumulate more fats, which hints at a metabolic component.
Luke
But do we know the mechanism? Is it the fats causing the aggression, or is the aggression causing the fats to accumulate?
Mimi
That's still being worked out. The study shows the correlation and that blocking the protein helps, but the full causal chain isn't mapped yet.
Mark
Why does this matter for treatment?
Mimi
Because you can't just kill all neutrophils—you'd lose your ability to fight infection. But if you can specifically target the rogue ones, you get inflammation control without immunosuppression.
Luke
And blocking that one protein actually achieves that? Or is it just a proof of concept?
Mimi
It reduced harmful effects in their experiments. Whether it translates to safe human treatment is the next step.
Il Polso
- Chronic inflammatory and autoimmune diseases have long resisted treatment in part because suppressing neutrophils broadly risks dismantling the body's defenses against infection entirely.
- A distinct subpopulation of 'rogue' neutrophils — longer-lived, more aggressive, and laden with accumulated fats — has now been identified as the specific driver of tissue damage in conditions like lupus, rheumatoid arthritis, and severe Covid-19.
- Metabolic dysfunction, particularly poor liver health, appears to trigger the transformation of ordinary neutrophils into these harmful variants, linking immune behavior directly to metabolic stress.
- Researchers identified a surface protein unique to rogue neutrophils that actively drives inflammatory damage — not merely marks it — making it a precise therapeutic target.
- Blocking that protein in experiments reduced tissue damage and excess inflammation without compromising the immune system's ability to fight infection, pointing toward safer, more targeted treatments on the horizon.
Within the body's vast immune architecture, not all defenders serve the same purpose — some, it turns out, become the very source of harm they were meant to prevent. Researchers at India's Central Drug Research Institute have identified a rogue subpopulation of neutrophils that linger far longer than their counterparts, driving chronic inflammation in conditions ranging from rheumatoid arthritis to fatty liver disease. The discovery, published in Cell Reports, suggests that the line between protection and destruction is drawn not by the immune system as a whole, but by specific cells within it — and that targeting those cells precisely may finally offer a path to treatment without leaving the body defenseless.
The immune system's neutrophils are its most numerous foot soldiers, accounting for up to 70 percent of all white blood cells. Their job is efficient and familiar: engulf pathogens, summon reinforcements, clear the wreckage. But researchers at India's Central Drug Research Institute, publishing in Cell Reports, have found that a subset of these cells operates by a different and far more destructive logic.
Dr. Sachin Kumar's team identified a distinct population of neutrophils that persist in the body longer than normal and fuel aggressive, lasting inflammation. These cells accumulate especially in the liver and appear across a range of serious conditions — rheumatoid arthritis, lupus, fatty liver disease, and severe Covid-19. Unlike ordinary neutrophils, which help resolve infection, these rogue variants transform a temporary immune response into a chronic one, inflicting ongoing tissue damage in the process.
Using high-resolution microscopy and cell sorting, the researchers found that inflammatory signals and metabolic stress — particularly compromised liver health — can cause normal neutrophils to shift into this more harmful form. The rogue cells also carry significantly more stored lipids, suggesting fat metabolism plays a role in their behavior and opening a new lens through which chronic inflammation can be understood.
The longstanding obstacle in treating neutrophil-driven disease has been the risk of leaving patients vulnerable to infection by suppressing these cells too broadly. The team's key advance was identifying a specific surface protein on rogue neutrophils that does not merely signal disease but actively drives the inflammatory damage. Blocking it reduced tissue harm without appearing to weaken the broader immune response — a distinction that transforms the protein from a diagnostic marker into a genuine therapeutic target.
By establishing that neutrophils are not a uniform force but a diverse population with meaningfully different behaviors, the researchers have moved from describing a problem to locating a precise point of intervention — one that could, in time, offer patients with chronic inflammatory diseases treatment that spares what protects them.
The body's immune system relies on white blood cells to stand guard against infection. Among these defenders, neutrophils make up the majority—between 60 and 70 percent of the total white blood cell count. They work by engulfing pathogens, releasing chemical signals that call other immune cells to the scene, and cleaning up the debris once the threat has passed. It is straightforward, efficient work. But researchers at India's Central Drug Research Institute have discovered that not all neutrophils behave the same way, and some of them cause far more harm than good.
Dr. Sachin Kumar's team, publishing their findings in Cell Reports, identified a distinct subpopulation of neutrophils that persist in the body longer than their counterparts and drive aggressive inflammation. These cells accumulate in the liver especially, and they appear in both acute and chronic inflammatory conditions—including rheumatoid arthritis, lupus, fatty liver disease, and severe cases of Covid-19. The distinction matters because while ordinary neutrophils help contain infection, these "rogue" neutrophils linger and inflict tissue damage, transforming what should be a temporary immune response into a chronic one.
The researchers used high-resolution microscopy and cell sorting techniques to examine these cells closely. What they found was revealing: inflammatory signals and metabolic stress—particularly poor liver health—can cause regular neutrophils to transform into the more aggressive variant. The rogue cells also store significantly more lipids and fats inside them, suggesting that changes in fat metabolism may influence their behavior. This connection between metabolic dysfunction and immune cell transformation opens a new angle for understanding how chronic inflammation develops.
The challenge in treating neutrophil-driven disease has always been the same: targeting these cells risks leaving the body defenseless against infection. Blocking or eliminating neutrophils wholesale could solve the inflammation problem but create a worse one. The researchers' breakthrough came when they identified a specific protein on the surface of rogue neutrophils and tested what happened when they blocked it. The result was significant. Blocking this protein reduced tissue damage and excess inflammation without apparently compromising the immune system's ability to fight infection. The protein is not merely a marker of disease—it appears to actively drive the inflammatory damage.
This distinction between a passive indicator and an active driver changes everything about how researchers might approach treatment. By establishing that rogue neutrophils form a distinct population with unique functional characteristics, the team has moved beyond simply describing the problem to identifying a potential point of intervention. The findings advance understanding of neutrophil heterogeneity—the fact that these cells are not a monolithic force but a diverse population with different behaviors and roles. For patients with chronic inflammatory and autoimmune diseases, the implication is clear: future treatments might be able to target the specific cells causing harm while leaving the protective immune response intact.
Citazioni salienti
Identifying disease-associated neutrophil populations is essential for targeted strategies, since therapeutic targeting has been challenging due to infection risk— Study published in Cell Reports
By establishing the presence and relevance of rogue neutrophils in inflammatory settings, findings significantly advance understanding of neutrophil heterogeneity and function— Research team at CSIR-CDRI
Vuoi la storia completa?
Leggi l'originale su The Tribune ↗
General News